Miliary Tuberculosis: A Comprehensive Review of Epidemiology, Clinical Manifestations, Diagnosis, Treatment, and Complications.
This comprehensive review synthesizes epidemiology, clinical manifestations, diagnostic approaches, treatment regimens, complications, and preventive evidence for miliary tuberculosis, including CNS disease, drug-resistant infection, TB-IRIS, and childhood BCG vaccination.
Open original publication →What the AI sees
This comprehensive review synthesizes epidemiology, clinical manifestations, diagnostic approaches, treatment regimens, complications, and preventive evidence for miliary tuberculosis, including CNS disease, drug-resistant infection, TB-IRIS, and childhood BCG vaccination.
Research significance
The supplied review reports established and emerging management approaches—including prolonged CNS-directed therapy, dexamethasone for CNS complications, individualized drug-resistant regimens, and TNF-α antagonists as salvage therapy for steroid-refractory TB-IRIS; it can only be inferred, not concluded from this record, that these insights might help manage tuberculosis in immunocompromised pediatric oncology patients, because that population is not specifically evaluated.
Source abstract
Miliary tuberculosis (TB) represents a potentially fatal form of disseminated TB resulting from the lymphohematogenous dissemination of Mycobacterium tuberculosis. Although accounting for approximately 1-2% of all TB cases in immunocompetent adults, its mortality rate exceeds 30%. This review screened peer-reviewed, original research studies via four databases (PubMed, EMBASE, MEDLINE, and CENTRAL) to synthesize up-to-date evidence. Key risk factors include human immunodeficiency virus (HIV) co-infection, anti-tumor necrosis factor-α (TNF-α) agents and chronic malnutrition. The clinical presentation of miliary TB is notoriously nonspecific, with fever, night sweats, weight loss, and constitutional symptoms predominating. Over 60% of patients have extrapulmonary complications, with central nervous system (CNS) involvement in 10-30%, abdominal involvement in 15-30%, and skeletal involvement in up to 17%. Laboratory abnormalities are common, including elevated erythrocyte sedimentation rate (ESR), anemia, lymphopenia, and nearly universal C-reactive protein (CRP) elevation. Diagnoses remain difficult due to paucibacillary lesions; novel molecular assays and a validated CNS prediction scoring system greatly improve diagnostic efficiency, while multiple microbiological and invasive tissue sampling modalities are briefly summarized for comprehensive clinical reference. Standard 6-month isoniazid, rifampicin, pyrazinamide ethambutol and isoniazid, rifampicin (HRZE-HR) regimens apply to isolated pulmonary miliary TB, whereas 9-12-month extended therapy plus adjunctive dexamethasone is required for CNS complications. Drug resistant cases demand 18-24-month individualized regimens with high blood-brain barrier penetration. Severe complications including tuberculous meningitis and high mortality acute respiratory distress syndrome (ARDS) are fully discussed, and TNF-α antagonists act as salvage therapy for steroid-refractory tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS). Bacillus Calmette-Guérin (BCG) vaccination provides substantial protection against miliary TB in children, with efficacy of approximately 77% and favorable cost-effectiveness. Existing reviews lack integrated post-pandemic epidemiological data, cutting-edge molecular diagnostics and modern extrapulmonary treatment algorithms; this paper fills such gaps to offer balanced clinical guidance for frontline clinicians.